Scarica l'app Stockscreener
90.76
0.90%
0.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$89.86
Aprire:
$90.285
Volume 24 ore:
2.88M
Relative Volume:
0.53
Capitalizzazione di mercato:
$281.38B
Reddito:
$58.07B
Utile/perdita netta:
$9.40B
Rapporto P/E:
30.14
EPS:
3.0113
Flusso di cassa netto:
$9.87B
1 W Prestazione:
+0.42%
1M Prestazione:
+1.25%
6M Prestazione:
+28.14%
1 anno Prestazione:
+40.27%
Intervallo 1D:
$90.19
$91.14
Intervallo di 1 settimana:
$89.28
$91.79
Portata 52W:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
90.75 | 278.62B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Buy |
| 2025-10-16 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
[XMAS PERIOD] LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive Investors
Daiichi Sankyo, AstraZeneca apply for second EU approval for Datroway - marketscreener.com
Texas Permanent School Fund Corp Has $4.94 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo - Medical Dialogues
Anastrozole Tablets Market is Thriving Worldwide | AstraZeneca - openPR.com
Assenagon Asset Management S.A. Sells 569,162 Shares of AstraZeneca PLC $AZN - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys AstraZeneca PLC (NASDAQ:AZN) Stock - MarketBeat
Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Nigeria
AstraZeneca stock: positive regulatory news and strong technical base drive 1.17% advance - Traders Union
Compugen rises on royalty deal with AstraZeneca - MSN
Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha
Compugen monetizes portion of cancer drug royalties to AstraZeneca By Investing.com - Investing.com South Africa
Sanders Morris Harris LLC Invests $950,000 in AstraZeneca PLC $AZN - MarketBeat
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - marketscreener.com
AstraZeneca Partners with Lebanese Health Ministry on Lung Cancer Awareness - marketscreener.com
AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen - Benzinga
AstraZeneca (AZN) Receives EU Approval for Saphnelo Self-Adminis - GuruFocus
AstraZeneca receives EU approval for subcutaneous Saphnelo self-administration By Investing.com - Investing.com South Africa
AstraZeneca PLCEnhertu approved in US for 1L HER2+ metastatic BC - Research Tree
AstraZeneca chalks up dual regulatory wins in cancer and immunology - Vox Markets
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca update within FTSE 350 and FTSE 100 healthcare landscape - Kalkine Media
AstraZeneca and Daiichi Sankyo's Enhertu approved as first-line therapy for HER2+ breast cancer - marketscreener.com
AstraZeneca’s Saphnelo approved in EU for self-administration in lupus By Investing.com - Investing.com UK
AstraZeneca Receives EU Approval for Pre-filled Pen for Lupus - marketscreener.com
AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer - DirectorsTalk Interviews
AstraZeneca says subcutaneous Saphnelo approved in EU - marketscreener.com
REGAstraZeneca PLCSubcutaneous Saphnelo approved in EU - TradingView — Track All Markets
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US - marketscreener.com
AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment - marketscreener.com
AstraZeneca Withdraws Andexxa, Unable To Find Path Forward With US FDA - Citeline News & Insights
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
AstraZeneca PLC ADR Underperforms Monday When Compared To Competitors Despite Daily Gains - 富途牛牛
AstraZeneca (AZN) and Daiichi Sankyo's Enhertu Combo Gains FDA A - GuruFocus
AstraZeneca (AZN) Gains FDA Approval for Breast Cancer Treatment - GuruFocus
AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval - Seeking Alpha
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment - Reuters
AstraZeneca and Daiichi Sankyo's enhertu gets US cancer approval - marketscreener.com
AstraZeneca (AZN) Gains FDA Approval for Enhertu in Breast Cance - GuruFocus
Geneos Wealth Management Inc. Grows Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
How New Deals and Diverging Analyst Views Are Rewriting the Story for AstraZeneca - Yahoo Finance
Holocene Advisors LP Sells 124,752 Shares of AstraZeneca PLC $AZN - MarketBeat
Rexford Capital Inc. Invests $948,000 in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Unveils Sweeping Blood Cancer Push With Record ASH Presence - MyChesCo
Why is AstraZeneca PLC (AZN) one of the best pharma stocks to invest in? - MSN
AstraZeneca PLC $AZN Shares Bought by Cubist Systematic Strategies LLC - MarketBeat
AstraZeneca PLC $AZN Shares Bought by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients - Benzinga
AstraZeneca (AZN) At the Center of Serious Analyst Attention - Insider Monkey
Parkwood LLC Buys 112,053 Shares of AstraZeneca PLC $AZN - MarketBeat
Federated Hermes Inc. Has $10.83 Million Stake in AstraZeneca PLC $AZN - MarketBeat
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):